WALTHAM, Mass.--(BUSINESS WIRE)--March 2, 2004--Beyond Genomics, Inc. today announced the appointment of Stelios Papadopoulos, Ph.D., to its Board of Directors. Dr. Papadopoulos is a Vice Chairman of SG Cowen Securities Corporation and an investment banker focused on the biotechnology and pharmaceutical sectors. \
"I am excited to join Beyond Genomics' Board of Directors," said Dr. Papadopoulos. "Beyond Genomics is an innovative company that has developed a pioneering systems biology platform for drug discovery and development. I look forward to working with the Company as it continues to make progress with its growing number of pharmaceutical and biotech partners, and as it advances its own internal research."
Muz Mansuri, PhD, Beyond Genomics' Executive Chairman, said, "We are fortunate to have someone with Stelios' experience and skill on our Board. Stelios brings new expertise and perspective to the Board as Beyond Genomics continues to evolve its product focus and extend its leadership in systems biology."
About Dr. Papadopoulos
Prior to joining SG Cowen in February 2000, Dr. Papadopoulos spent 13 years as an investment banker at PaineWebber, Incorporated where he was most recently Chairman of PaineWebber Development Corporation, a PaineWebber subsidiary focusing on biotechnology. He joined PaineWebber in April 1987 from Drexel Burnham Lambert where he was a vice president in the Equity Research Department covering the biotechnology industry. Prior to Drexel, he was a biotechnology analyst at Donaldson, Lufkin & Jenrette.
Before coming to Wall Street, Dr. Papadopoulos was on the faculty of the Department of Cell Biology at New York University Medical Center. He continues his affiliation with NYU Medical Center as an Adjunct Associate Professor of Cell Biology. Dr. Papadopoulos holds a PhD in biophysics and an MBA in finance, both from New York University.
Dr. Papadopoulos is a co-founder and Chairman of the Board of Exelixis, Inc., and he is a co-founder and member of the Board of CellZome, Inc. and of Anadys Pharmaceuticals, Inc. He is also a member of the Board of Directors of GenVec, Inc., and Structural GenomiX, Inc. In the not-for-profit sector, Dr. Papadopoulos is a co-founder and Chairman of Fondation Sante.
About Beyond Genomics
Founded in 2000, Beyond Genomics is an emerging biotechnology company that applies its proprietary Systems Biology platforms to develop novel therapeutics and biomarkers. Current approaches such as genomics and proteomics focus on one aspect of biological systems at a time. Rather than simplifying the inherent complexity of biological processes that underlie human diseases or that govern drug responses, Beyond Genomics has pioneered the creation of Molecular Phenotypes(TM) to enable biological research at the systems level. BG develops Molecular Phenotypes(TM) unique to each disease and drug category by performing multiple measurements on complex biological samples, including metabolites, proteins and gene transcripts, and combining these data sets together with clinical information. Tracking changes in Molecular Phenotypes(TM) can improve multiple aspects of pharmaceutical discovery and development, including drug safety and efficacy, drug response, and the etiology of disease. BG's Systems Biology platform integrates state-of-the-art technologies in proteomics, metabolomics, and bioinformatics. The company has also developed a proprietary BioSystematics(TM) data integration and knowledge management platform that generates connections, correlations, and relationships among thousands of measurable molecular components. The company has partnerships with several pharmaceutical and biotechnology companies, including GlaxoSmithKline, Novartis, AstraZeneca, and Elan. www.beyondgenomics.com.
Beyond Genomics, Inc. Ted Marple, 781-890-1199 info@BeyondGenomics.com
Source: Beyond Genomics, Inc.